Table 1.
Characteristics of medication dataset at baseline. Only the time up to the first SRC is considered
| Patients with SRC (N = 102) | Patients without SRC (N = 7546) | Median # or risk difference (95% CI) | P value | |
|---|---|---|---|---|
| Median (IQR) or no. of patients (%) | ||||
| Age (years) | 57.3 (48.0 to 67.9) | 56.4 (46.0 to 65.7) | 1.3 (− 1.3 to 3.9) | 0.36 |
| Sex (female) | 80/102 (78%) | 6484/7546 (86%) | − 7% (− 16 to 1%) | 0.031 |
| Time between onset of scleroderma and inclusion (y)* | 5.0 (1.9 to 10.9) | 7.0 (3.1 to 13.2) | − 1.3 (− 2.5 to − 0.3) | 0.019 |
| Extent of skin involvement | 0.005 | |||
| No skin involvement | 4/100 (4%) | 306/7312 (4%) | ||
| Only sclerodactyly | 11/100 (11%) | 785/7312 (11%) | ||
| Limited cutaneous involvement | 41/100 (41%) | 4151/7312 (57%) | ||
| Diffuse cutaneous involvement | 44/100 (44%) | 2070/7312 (28%) | ||
| Glucocorticoids | 37/90 (41%) | 2437/6644 (37%) | 4% (− 6 to 15%) | 0.39 |
| Dose at baseline (if > 0), mg | 7.5 (5.0 to 10.0) | 5.0 (5.0 to 10.0) | 0.0 (0.0 to 2.0) | 0.16 |
| Glucocorticoids > 10 mg | 5/90 (6%) | 295/6644 (4%) | 1% (− 4 to 6%) | 0.61 |
| Glucocorticoids > 15 mg | 3/90 (3%) | 171/6644 (3%) | 1% (− 3 to 4%) | 0.65 |
| ACE inhibitors | 34/96 (35%) | 1299/7163 (18%) | 17% (8 to 27%) | < 0.001 |
| Angiotensin receptor blocker | 6/96 (6%) | 654/7150 (9%) | − 3% (− 8 to 2%) | 0.33 |
| Calcium channel blockers | 50/96 (52%) | 3763/7178 (52%) | − 0% (− 10 to 10%) | 0.95 |
| Endothelin receptor antagonist | 12/85 (14%) | 727/6165 (12%) | 2% (− 5 to 10%) | 0.51 |
| PDE5 inhibitors | 6/91 (7%) | 321/6649 (5%) | 2% (− 3 to 7%) | 0.44 |
*Missing data for 10 patients with and 982 patients without SRC
#Generalized Hodges-Lehmann median differences